{"success":true,"data":{"pressRelease":{"id":"166022","rtpr_id":"nPnc2f3BPa-20261012","ticker":"AARD","exchange":"NASDAQ","all_tickers":["AARD"],"title":"Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD","author":"PR Newswire","published_at":"2026-10-12T06:29:00.079Z","article_body":"Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD\nPR Newswire\n\nNEW YORK, Oct. 12, 2026\n\nNEW YORK, Oct. 12, 2026 /PRNewswire/ -- The DJS Law Group\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795290-1&h=2981294603&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group)\n reminds investors of a class action lawsuit against Aardvark Therapeutics,\nInc. (\"Aardvark\" or \"the Company\") (NASDAQ: AARD\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795290-1&h=294815636&u=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2FAARD&a=AARD)\n) violations of the federal securities laws.\n\nShareholders who purchased shares of AARD during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: Pursuant and/or traceable to the Company's February 13, 2025,\ninitial public offering (\"IPO\") and/or from February 13, 2025 to May 14, 2026.\n\nDEADLINE: October 13, 2026\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Aardvark misled investors about the\ncommercial prospects of its ARD-101 drug candidate. Based on these facts,\nAardvark's public statements were false and materially misleading throughout\nthe IPO period.\n\nIf you are a shareholder who suffered a loss, contact us to participate\n(mailto:David@djslawllp.com) .\n\nWHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor\nreturn through balanced counseling and aggressive advocacy. We specialize in\nsecurities class actions, corporate governance litigation, and\ndomestic/international M&A appraisals. Our clients are some of the largest\nand most sophisticated hedge funds and alternative asset managers in the\nworld. The litigation claims of our clients are extraordinarily valuable\nassets that demand respect, focus, and results.\n\nJoin the case (mailto:David@djslawllp.com)  to recover your losses.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\nCONTACT:\n\nDavid J. Schwartz\n\nDJS Law Group\n\n274 White Plains Road, Suite 1\n\n Eastchester, NY 10709\n\nPhone: 914-206-9742\n\nEmail: David@djslawllp.com (mailto:David@djslawllp.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights---aard-302905274.html\n(https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights---aard-302905274.html)\n\nSOURCE DJS Law Group LLP\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnc2f3BPa-20261012","title":"Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD","author":"PR Newswire","ticker":"AARD","created":"2026-10-12T06:29:00.079Z","tickers":["AARD"],"exchange":"NASDAQ","article_body":"Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD\nPR Newswire\n\nNEW YORK, Oct. 12, 2026\n\nNEW YORK, Oct. 12, 2026 /PRNewswire/ -- The DJS Law Group\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795290-1&h=2981294603&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group)\n reminds investors of a class action lawsuit against Aardvark Therapeutics,\nInc. (\"Aardvark\" or \"the Company\") (NASDAQ: AARD\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795290-1&h=294815636&u=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2FAARD&a=AARD)\n) violations of the federal securities laws.\n\nShareholders who purchased shares of AARD during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: Pursuant and/or traceable to the Company's February 13, 2025,\ninitial public offering (\"IPO\") and/or from February 13, 2025 to May 14, 2026.\n\nDEADLINE: October 13, 2026\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Aardvark misled investors about the\ncommercial prospects of its ARD-101 drug candidate. Based on these facts,\nAardvark's public statements were false and materially misleading throughout\nthe IPO period.\n\nIf you are a shareholder who suffered a loss, contact us to participate\n(mailto:David@djslawllp.com) .\n\nWHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor\nreturn through balanced counseling and aggressive advocacy. We specialize in\nsecurities class actions, corporate governance litigation, and\ndomestic/international M&A appraisals. Our clients are some of the largest\nand most sophisticated hedge funds and alternative asset managers in the\nworld. The litigation claims of our clients are extraordinarily valuable\nassets that demand respect, focus, and results.\n\nJoin the case (mailto:David@djslawllp.com)  to recover your losses.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\nCONTACT:\n\nDavid J. Schwartz\n\nDJS Law Group\n\n274 White Plains Road, Suite 1\n\n Eastchester, NY 10709\n\nPhone: 914-206-9742\n\nEmail: David@djslawllp.com (mailto:David@djslawllp.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights---aard-302905274.html\n(https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights---aard-302905274.html)\n\nSOURCE DJS Law Group LLP\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-12T06:29:00.123973354Z","server_sent_at_ms":1791786540123},"received_at":"2026-10-12T06:29:00.175Z","source_url":"https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights---aard-302905274.html"},"analysis":{"id":"154399","press_release_id":"166022","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Securities class action alleges misleading statements on ARD-101 commercial prospects tied to the February 2025 IPO"],"eventType":"legal_litigation","narrative":"DJS Law Group issued a shareholder-solicitation notice announcing a securities class action against Aardvark Therapeutics, with a lead plaintiff deadline of October 13, 2026.\n\nThe complaint alleges the company misled investors about the commercial prospects of its ARD-101 drug candidate in connection with its February 2025 IPO.\n\nThis is law-firm marketing rather than an issuer disclosure; the suit's existence is noted but the release contains no new company information or court ruling.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation on an existing class action -- suppress."},"keyFigures":{},"quotedText":"Aardvark misled investors about the commercial prospects of its ARD-101 drug candidate.","namedEntities":{"people":[{"name":"David J. Schwartz","role":"DJS Law Group contact attorney"}],"products":["ARD-101"],"companies":[{"name":"DJS Law Group","relationship":"plaintiff law firm"},{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"target of class action"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by DJS Law Group reminding investors of a class action and lead plaintiff deadline. No issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"AARD"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"DJS Law Group issued a shareholder-solicitation notice announcing a securities class action against Aardvark Therapeutics, with a lead plaintiff deadline of October 13, 2026.\n\nThe complaint alleges the company misled investors about the commercial prospects of its ARD-101 drug candidate in connection with its February 2025 IPO.\n\nThis is law-firm marketing rather than an issuer disclosure; the suit's existence is noted but the release contains no new company information or court ruling.","key_figures":{},"named_entities":{"people":[{"name":"David J. Schwartz","role":"DJS Law Group contact attorney"}],"products":["ARD-101"],"companies":[{"name":"DJS Law Group","relationship":"plaintiff law firm"},{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"target of class action"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T06:29:04.742Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4549,"modelName":"glm-5.3-flashx"}}